Subcutaneous Efgartigimod Expands Payer Potential For Argenx’s Drug

Offers gMG Patients Freedom From I.V. Treatment

 
• By Alaric DeArment
  
Infusion of a hospital
argenx announced topline results for its subcutaneous formulation of efgartigimod • Source: Shutterstock

More from Immunological

More from Therapy Areas